PLAying with liposomes

A Danish group has developed liposomes that are prodrugs that potentially could be activated at tumor sites via a tumor-specific enzymatic reaction.¹ The IP has been licensed to LiPlasome Pharma A/S, which already has an earlier version of the liposome technology for the enzymatic release of cisplatin in Phase I testing in solid tumors.

Liposomes are artificial lipid vesicles that can be used to encapsulate a therapeutic agent and protect it from degradation. In principle, liposomes can extend the activity of cancer therapeutics or deliver a payload to specific tissues and thus avoid side effects.²...